Anzeige
Mehr »
Dienstag, 23.09.2025 - Börsentäglich über 12.000 News
Avanti Gold steigt um 1.500% - und steht womöglich erst am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
23.09.25 | 09:31
239,00 Euro
+0,29 % +0,70
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
237,80238,9011:49
237,80238,9011:48
PR Newswire
941 Leser
Artikel bewerten:
(2)

Veeva Systems: Veeva and Zifo Partner to Accelerate Quality Control Modernization

Integration will reduce the burden of master lab data configuration, lowering costs and speeding Veeva LIMS implementation

BARCELONA, Spain and DEERFIELD, Ill., Jan. 23, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Zifo today announced a product partnership to help biopharmas modernize quality control (QC) operations. By bringing together Veeva LIMS with Zifo's data integration and management platform, qcKen, companies can import data directly from any source document or other LIMS into Veeva LIMS. This integration will simplify master data configuration during LIMS implementation and site deployment, making it easier for companies to advance beyond legacy QC systems.

Veeva Systems

"We are excited to partner with Veeva to offer powerful solutions to the life sciences industry," said Kannan Jagamoorthy, general manager and head of Zifo North America. "Our collaboration will help customers expedite their adoption of Veeva LIMS to streamline operations."

With Veeva, companies take a holistic approach to quality assurance (QA) and QC to support GMP quality business processes with greater accuracy. Using Zifo's qcKen will help accelerate test and specification data creation, streamline implementation and site deployments, and deliver a faster return on investment for new Veeva LIMS customers.

"Veeva LIMS is designed specifically for life sciences organizations looking to advance their QC operations, increase scale, and speed batch release cycles," said Ashley McMillan, senior director, Veeva LIMS strategy. "Partnering with Zifo allows customers to implement Veeva LIMS and realize value much quicker, accelerating QC modernization initiatives."

As part of the partnership, Zifo is an official Veeva Product Partner, building on its existing relationship as a Veeva Services Partner. Watch this to learn how a unified cloud LIMS can improve right first time and accelerate batch release.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

About Zifo
Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit zifornd.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/veeva-and-zifo-partner-to-accelerate-quality-control-modernization-302358022.html

© 2025 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.